Cardiovascular outcomes · Phase 3
SELECT: cardiovascular outcomes
What was tested?
Subcutaneous semaglutide versus placebo in people with established cardiovascular disease. ↗
Registered primary question: Time to the first cardiovascular death, nonfatal heart attack or nonfatal stroke; the registry observation window extended to 240 weeks. ↗
What the reviewed report found
Journal year 2023 · Article summary reviewed 2026-08-18
A primary cardiovascular event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group; the reported hazard ratio was 0.80. Permanent discontinuation because of adverse events occurred in 16.6% and 8.2%, respectively.↗
Keep in context: The report gives a mean follow-up of 39.8 months. That observed follow-up differs from the maximum registry observation window. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 17,604 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Quadruple
- Design
- Parallel
- Eligible ages
- 45 Years; maximum not specified
- Registry results
- Posted in this snapshot
Registry source ↗ · Updated 2024-08-30; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
SELECT cardiovascular-outcomes trial
- Design in the report
- A multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial assessed a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.↗
- Participants in the report
- The trial enrolled 17,604 adults age 45 or older with established cardiovascular disease and overweight or obesity, but no history of diabetes.↗
- Limitations
- The sponsor-funded findings apply to people with preexisting cardiovascular disease and without diabetes; they do not answer primary prevention for lower-risk populations.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity ↗
Protocol identifier: EX9536-4388. Sponsor: Novo Nordisk A/S.
Retrieved 2026-09-20; SHA-256 661d514b49ddde12d10833d95755d2d7776b116fabc760abaf8b7e5f382a8899.
PMID 37952131
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ↗
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference RESULT. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 37952131. SHA-256 f2177628b98083064df17512c3dd229b760887c00cc64c4cfa4fc4e49523b12a.
Scientific summary uses the original 2026-08-18 source snapshot: SHA-256 dabd7cd9d6c08b9c07da39a19d0b48266bfb7ddbbaacefe2e11025d105708245.